Completed × Esophageal Squamous Cell Carcinoma × Cisplatin × Clear all Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Phase 2 Completed
26 enrolled 6 charts
PPIO-004-EC001
Phase 2 Completed
118 enrolled
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Phase 3 Completed
649 enrolled 22 charts
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Phase 2 Completed
52 enrolled
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Phase 2 Completed
50 enrolled
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
Phase 1 Completed
37 enrolled
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Phase 3 Completed
370 enrolled
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
Phase 2 Completed
30 enrolled
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Phase 3 Completed
746 enrolled
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2 Completed
28 enrolled
Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma
Phase 2 Completed
46 enrolled
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Phase 3 Completed
344 enrolled 11 charts
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Phase 2 Completed
245 enrolled 15 charts
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Phase 3 Completed
297 enrolled
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Phase 1 Completed
32 enrolled
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
Phase 3 Completed
195 enrolled
A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
Phase 3 Completed
436 enrolled
Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer
Phase NA Completed
220 enrolled
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Phase 2 Completed
43 enrolled 5 charts
Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
Phase 3 Completed
56 enrolled
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
Phase 1/2 Completed
33 enrolled
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
Phase 2 Completed
57 enrolled
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
Phase 2/3 Completed
266 enrolled
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Phase 2 Completed
16 enrolled 6 charts
Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
Phase 2 Completed
80 enrolled
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
Phase 2 Completed
19 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
Phase 2 Completed
21 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
Phase 3 Completed
298 enrolled
Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus
Phase 3 Completed
240 enrolled
Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach
Phase 2 Completed
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
Phase 1 Completed
24 enrolled
Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus
Phase 2 Completed
25 enrolled
Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer
Phase 2 Completed
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
Phase 1 Completed
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
Phase 2 Completed
Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer
Phase 1 Completed
27 enrolled
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Phase 1/2 Completed
27 enrolled
Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
Phase 2 Completed
66 enrolled
Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
21 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
Phase 1/2 Completed
26 enrolled
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer
Phase 2 Completed
14 enrolled